Galapagos reports Phase II CF data for GLPG2222 combo

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said cystic fibrosis candidate GLPG2222 plus Kalydeco ivacaftor significantly reduced sweat chloride levels vs. placebo plus Kalydeco in the Phase II ALBATROSS trial. The trial enrolled 37 CF patients on long-term stable treatment with Kalydeco who had a delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) mutation and a gating mutation.

Galapagos said the data will inform dose selection for a triple combination trial that is expected to start this quarter. The trial will evaluate GLPG2222 in combination with a CFTR potentiator and a late binding CFTR corrector. GLPG2222 is an early binding CFTR corrector, and Kalydeco is a CFTR potentiator from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)...